0001104659-26-059422
SEC filingRezolute reported narrower operating and net losses in Q3 FY2026 versus prior year, reflecting reduced ersodetug R&D spending following sunRIZE enrollment completion and manufacturing de-escalation — yet operating cash outflows widened, underscoring continued capital intensity ahead of pivotal clinical readouts.
Net income for Q3 FY2026 was -$16.2 million, an improvement of 14.5% versus -$18.9 million in the prior-year quarter. Diluted EPS was $-0.16, an improvement of 40.7% compared to $-0.27 in Q3 FY2025. The larger percentage improvement in EPS relative to net income reflects a lower weighted-average diluted share count, consistent with the company’s capital structure activity during the period.
Net cash used in operating activities was -$47.1 million for Q3 FY2026, compared to -$38.8 million in Q3 FY2025. While interest income increased modestly — supported by higher average balances in marketable debt securities — this did not offset the underlying operational cash outflows. The widening reflects the timing and magnitude of payments related to ongoing clinical and regulatory activities, as well as working capital movements across accounts payable and accrued liabilities.